All In Biotech

Drug Trial Radar · NCT05890053

To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia

A 52-week, Open Phase III Study Evaluating the Long-term Safety and Efficacy of HSK16149 Capsules in Chinese Patients With Peripheral Neuralgia

Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Feb 17, 2022

Primary completion

Jul 30, 2023

Study completion Aug 7, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigate the long-term(52 weeks) safety and efficacy of HSK16149 capsules in Chinese patients with periphcral neuralgia

Conditions

  • Peripheral Neuropathic Pain

Interventions

  • HSK16149 40mg BIDDrug

    HSK16149 40mg , orally twice a day, treatment period; 52-weeks fixed dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the long-term safety of HSK16149 capsules in Chinese patients with peripheral neuralgia.Time frame: From week 1 to week 53

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Pinggu District Hospital

    Beijing, Beijing Municipality, China

  • Emergency General Hospital

    Beijing, Beijing Municipality, China

  • The Three Gorges Hospital Affiliated to Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China

  • The Third Hospital of Hebei Medical University

    Shijiangzhuang, Hebei, China

  • Kaifeng Hospital of Traditional Chinese Medicine

    Kaifeng, Henan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Nanyang First People's Hospital

    Nanyang, Henan, China

  • Wuhan Central Hospital

    Wuhan, Hubei, China

  • Nanjing First People's Hospital

    Nanjing, Jiangsu, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Baotou Central Hospital

    Baotou, Neimenggu, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • The First Affiliated Hospital of Xi'an Medical University

    Xi’an, Shanxi, China

  • Yuncheng Central Hospital

    Yuncheng, Shanxi, China

  • The Second People's Hospital of Yibin

    Yibin, Sichuan, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

  • Taizhou First People's Hospital

    Taizhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.